Encouraging start to the year for Bayer
- Details
- Category: Bayer
Sales of the Bayer Group advanced by 6.8 percent in the first quarter, to a record EUR 10,056 million (Q1 2011: EUR 9,415 million). Adjusted for currency and portfolio effects, business expanded by 5.2 percent. The operating result (EBIT) climbed by 42.6 percent to EUR 1,637 million (Q1 2011: EUR 1,148 million).
AstraZeneca and The Medicines Company announce global collaboration in acute ischaemic heart disease
- Details
- Category: AstraZeneca
AstraZeneca and The Medicines Company announced a global collaboration for their acute ischaemic heart disease compounds. The first part of this collaboration is a US co-promotion for AstraZeneca's oral antiplatelet medicine BRILINTA.
Amgen's first quarter 2012 revenue increased 9 percent to $4.0 billion
- Details
- Category: Amgen
Amgen (NASDAQ:AMGN) reported total revenue increased 9 percent during the first quarter of 2012 to $4,048 million versus $3,706 million in the first quarter of 2011. Adjusted earnings per share (EPS) were $1.61 for the first quarter of 2012, an increase of 20 percent compared to $1.34 for the first quarter of 2011.
Strong sales performance in pharmaceuticals and Alcon
- Details
- Category: Novartis
Novartis net sales declined by 2% (-1% cc) to USD 13.7 billion. Currency negatively impacted sales by 1% due to the strengthening of the dollar against many currencies. Products launched since 2007 drove the Group to strong volume growth of 5 percentage points versus the previous year.
Novo Nordisk and Oxford University team up to develop novel treatments
- Details
- Category: Novo Nordisk
Today, Novo Nordisk and the Kennedy Institute of Rheumatology at Oxford University jointly announced a new partnership to develop promising new drug candidates and identify novel biomarkers and treatment targets for rheumatoid arthritis and other autoimmune inflammatory diseases.
AstraZeneca to acquire Ardea Biosciences for $1 billion
- Details
- Category: AstraZeneca
AstraZeneca and Ardea Biosciences, Inc. (Ardea) have entered into a definitive merger agreement, pursuant to which AstraZeneca will acquire Ardea, a San Diego, California-based biotechnology company focused on the development of small-molecule therapeutics.
Novartis updates US label on Gilenya® following discussions with the FDA
- Details
- Category: Novartis
Novartis announced agreement with the US Food and Drug Administration (FDA) on label changes for Gilenya® (fingolimod). The update to the Gilenya prescribing information includes patient selection parameters to aid in the identification of candidates for Gilenya treatment and more specific recommendations for treatment initiation for patients with relapsing forms of MS in the United States.
More Pharma News ...
- GSK confirms offer to acquire Human Genome Sciences for US$13.00 per share in cash
- GSK provides update on corporate responsibility commitments in 2011 report
- Abbott's investigational treatment for advanced Parkinson's disease demonstrates positive results
- Roche on track for full-year targets - good sales growth in first quarter
- Takeda to Acquire URL Pharma
- UCB marks World Parkinson's Disease Day with new Parkinson's Well-Being Map™
- Amgen to acquire privately held KAI Pharmaceuticals